Search earnings tickers

ALNY

2024Q1BMO

Alnylam Pharmaceuticals Inc primary · HEALTHCARE · BIOTECHNOLOGY

Report 2024-05-02 · Fiscal end 2024-03-31 · Features as of 2024-05-01

← Earnings history

Street

Consensus EPS-0.63

Consensus rev—

EPS high—

EPS low—

Dispersion—

Analysts—

EPS rev net 7d—

EPS rev net 30d—

Consensus Δ 7d—

Consensus Δ 30d—

Options

Implied move2.3%

IV front—

P/C full—

P/C front—

Features as of2024-05-01

Run-up

Close—

Ret 5d+4.3%

Ret 10d+3.2%

Ret 20d-0.6%

Ret 30d+1.2%

Print

Actual EPS

-0.16Beat

Estimated EPS-0.63

Actual revenue

494.3M

Surprise %+74.6%

Beat / missBeat

Beat streak 41

Beat streak 81

Reaction

1-day stock reaction-0.3%

Implied vs actual

Implied 2.3%Actual 0.6%

Gap reaction+0.6%

Day result+0.2%

Next-day upNo

Realized / IV0.24×

Post tape

Post 5d+0.7%

Post 10d+0.6%

Post volume660.2K

Vol ×10d1.30×

Vol ×20d1.29×

Post range4.4%